Recent

% | $
Quotes you view appear here for quick access.

GlaxoSmithKline plc Message Board

  • usagary1 usagary1 Nov 19, 2012 11:54 AM Flag

    Things to watch for

    Revolade/Promacta(eltrombopag)† thrombopoietin receptor agonist hepatitis C induced thrombocytopaenia Phase III
    Tyverb/Tykerb (lapatinib) Her2 and EGFR dual kinase inhibitor head & neck squamous cell carcinoma (resectable disease) Phase III
    Tyverb/Tykerb (lapatinib) Her2 and EGFR dual kinase inhibitor gastric cancer Phase III
    Tyverb/Tykerb (lapatinib) human epidermal growth factor receptor-2 (Her2) and epidermal growth factor receptor (EGFR) dual kinase inhibitor breast cancer, adjuvant therapy Phase III
    Votrient (pazopanib) multi-kinase angiogenesis inhibitor ovarian cancer, maintenance therapy Phase III
    Votrient (pazopanib) multi-kinase angiogenesis inhibitor renal cell cancer, adjuvant therapy Phase III
    dabrafenib (2118436) BRaf protein kinase inhibitor metastatic melanoma Phase III
    trametinib (1120212)† MEK1/2 inhibitor metastatic melanoma Phase III
    Tyverb/Tykerb (lapatinib) Her2 and EGFR dual kinase inhibitor metastatic breast cancer, in combination with trastuzumab Submitted S: Feb12 S: Feb12
    Votrient (pazopanib) multi-kinase angiogenesis inhibitor sarcoma Submitted S: Jul11 S: Jun11

 
GSK
41.65-0.38(-0.90%)Jun 30 4:02 PMEDT